VISIT US AT ECCMID 2024 in Spain!
Date. 2024.04.05-
WHO and the Medicines Patent Pool (MPP) announce a license agreement with SD Biosensor Inc., a global in-vitro diagnostic company, to provide sublicensees with the right, know-how and material to manufacture SDB’s rapid diagnostic testing (RDT) technology. The transparent, non-exclusive license agreement, negotiated under the auspices of the COVID-19 Technology Access Pool (C-TAP), represents an important milestone in the evolution of the C-TAP initiative as it enables the manufacture of diagnostics for COVID-19 as well as other diseases such as HIV, malaria and syphilis.
-
SD Biosensor was officially invited to the JP Morgan Healthcare Conference and presented in the APAC & LaTam section on January 10 (local time).